Abstract
4501 Background: Genetic variations in gemcitabine transport and metabolism may affect the clinical response, toxicity, and prognosis of pancreatic cancer patients treated with gemcitabine. Methods: We evaluated 17 single nucleotide polymorphisms (SNPs) of 8 genes (CDA, dCK, RRM1, DCTD, hCNT1, hCNT2, hCNT3, and hENT1) involved in gemcitabine metabolism in a homogeneous population of 126 patients with resectable pancreatic cancer treated with neoadjuvant gemcitabine- based chemotherapy plus radiation therapy. Whole blood was collected from patients at the time of enrollment, and DNA was extracted from peripheral lymphocytes using a DNA isolation kit (Qiagen Valencia, CA). Polymorphisms were detected using the TaqMan genotyping assays provided by Applied Biosystems (Foster City, CA). Survival was determined from pathologic diagnosis to death or last follow-up. Kaplan-Meier plot, log-rank test, and Cox regression were used to compare survival of patients according to genotype. Results: Six of the 17 SNPs had...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
